| References |
|
|
Aartsma-Rus A and
van Ommen GJ
(2007)
Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.
RNA
13:
1609–1624.
|
|
|
Alves S,
Mangas M,
Prata MJ et al.
(2006)
Molecular characterization of Portuguese patients with mucopolysaccharidosis type II shows evidence that the IDS gene is prone to splicing mutations.
Journal of Inherited Metabolic Disease
29:
743–754.
|
|
|
Baralle D,
Lucassen A and
Buratti E
(2009)
Missed threads. The impact of pre-mRNA splicing defects on clinical practice.
EMBO Reports
10:
810–816.
|
|
|
Berget SM
(1995)
Exon recognition in vertebrate splicing.
Journal of Biological Chemistry
270:
2411–2414.
|
|
|
Biamonti G and
Caceres JF
(2009)
Cellular stress and RNA splicing.
Trends in Biochemical Sciences
34:
146–153.
|
|
|
Black DL
(2003)
Mechanisms of alternative pre-messenger RNA splicing.
Annual Review of Biochemistry
72:
291–336.
|
|
|
Blaustein M,
Pelisch F and
Srebrow A
(2007)
Signals, pathways and splicing regulation.
International Journal of Biochemistry & Cell Biology
39:
2031–2048.
|
|
|
Breathnach R,
Benoist C,
O'Hare K,
Gannon F and
Chambon P
(1978)
Ovalbumin gene: evidence for a leader sequence in mRNA and DNA sequences at the exon–intron boundaries.
Proceedings of the National Academy of Sciences of the USA
75:
4853–4857.
|
|
|
Buratti E and
Baralle D
(2010)
Novel roles of U1 snRNP in alternative splicing regulation.
RNA Biology
7:
412–419.
|
|
|
Buratti E and
Baralle FE
(2004)
Influence of RNA secondary structure on the pre-mRNA splicing process.
Molecular and Cellular Biology
24:
10505–10514.
|
|
|
Buratti E,
Chivers M,
Kralovicova J et al
(2007a)
Aberrant 5¢ splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization.
Nucleic Acids Research
35:
4250–4263.
|
|
|
Buratti E,
Dhir A,
Lewandowska MA and
Baralle FE
(2007b)
RNA structure is a key regulatory element in pathological ATM and CFTR pseudoexon inclusion events.
Nucleic Acids Research
35:
4369–4383.
|
|
|
Cartegni L,
Chew SL and
Krainer AR
(2002)
Listening to silence and understanding nonsense: exonic mutations that affect splicing.
Nature Reviews Genetics
3:
285–298.
|
|
|
Catterall JF,
O'Malley BW,
Robertson MA et al.
(1978)
Nucleotide sequence homology at 12 intron–exon junctions in the chick ovalbumin gene.
Nature
275:
510–513.
|
|
|
Chasin LA
(2007)
Searching for splicing motifs.
Advances in Experimental Medicine and Biology
623:
85–106.
|
|
|
Chen JM,
Ferec C and
Cooper DN
(2010)
Revealing the human mutome.
Clinical Genetics
78:
310–320.
|
|
|
Chen X,
Truong TT,
Weaver J et al.
(2006)
Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Hum Mutatation
27:
427–435.
|
|
|
Cooper DN,
Chen JM,
Ball EV et al.
(2010)
Genes, mutations, and human inherited disease at the dawn of the age of personalized genomics.
Hum Mutation
31:
631–655.
|
|
|
Crooke ST
(2004)
Antisense strategies.
Current Molecular Medicine
4:
465–487.
|
|
|
Davis RL,
Homer VM,
George PM and
Brennan SO
(2009)
A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment.
Hum Mutation
30:
221–227.
|
|
|
Dhir A and
Buratti E
(2010)
Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies.
FEBS Journal
277:
841–855.
|
|
|
Dominski Z and
Kole R
(1993)
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Proceedings of the National Academy of Sciences of the USA
90:
8673–8677.
|
|
|
Faa V,
Incani F,
Meloni A et al.
(2009)
Characterization of a disease-associated mutation affecting a putative splicing regulatory element in intron 6b of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Journal of Biological Chemistry
284:
30024–30031.
|
|
|
Fairbrother WG and
Chasin LA
(2000)
Human genomic sequences that inhibit splicing.
Molecular and Cellular Biology
20:
6816–6825.
|
|
|
Friedman KJ,
Kole J,
Cohn JA et al.
(1999)
Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides.
Journal of Biological Chemistry
274:
36193–36199.
|
|
|
Grellscheid SN and
Smith CW
(2006)
An apparent pseudo-exon acts both as an alternative exon that leads to nonsense-mediated decay and as a zero-length exon.
Molecular and Cellular Biology
26:
2237–2246.
|
|
|
Gurvich OL,
Tuohy TM,
Howard MT et al.
(2008)
DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Annals of Neurology
63:
81–89.
|
|
|
Hammond SM and
Wood MJ
(2011)
Genetic therapies for RNA mis-splicing diseases.
Trends in Genetics
27:
196–205.
|
|
|
Hertel KJ
(2008)
Combinatorial control of exon recognition.
Journal of Biological Chemistry
283:
1211–1215.
|
|
|
Llorian M and
Smith CW
(2011)
Decoding muscle alternative splicing.
Current Opinion in Genetics & Development (in press).
|
|
|
Lucien N,
Chiaroni J,
Cartron JP and
Bailly P
(2002)
Partial deletion in the JK locus causing a Jk(null) phenotype.
Blood
99:
1079–1081.
|
|
|
Luco RF and
Misteli T
(2011)
More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation.
Current Opinion in Genetics & Development (in press).
|
|
|
Madden HR,
Fletcher S,
Davis MR and
Wilton SD
(2009)
Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping.
Hum Mutation
30:
22–28.
|
|
|
Pagani F,
Buratti E,
Stuani C et al.
(2002)
A new type of mutation causes a splicing defect in ATM.
Nature Genetics
30:
426–429.
|
|
|
Pros E,
Fernandez-Rodriguez J,
Canet B et al.
(2009)
Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
Human Mutation
30:
454–462.
|
|
|
Raponi M,
Buratti E,
Llorian M et al.
(2008)
Polypyrimidine tract binding protein regulates alternative splicing of an aberrant pseudoexon in NF1.
FEBS Journal
275:
6101–6108.
|
|
|
Schwartz S,
Gal-Mark N,
Kfir N et al.
(2009)
Alu exonization events reveal features required for precise recognition of exons by the splicing machinery.
PLoS Computational Biology
5:
e1000300.
|
|
|
Sharma S,
Kohlstaedt LA,
Damianov A,
Rio DC and
Black DL
(2008)
Polypyrimidine tract binding protein controls the transition from exon definition to an intron defined spliceosome.
Nature Structural & Molecular Biology
15:
183–191.
|
|
|
Sierakowska H,
Sambade MJ,
Agrawal S and
Kole R
(1996)
Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides.
Proceedings of the National Academy of Sciences of the USA
93:
12840–12844.
|
|
|
Sironi M,
Menozzi G,
Riva L et al.
(2004)
Silencer elements as possible inhibitors of pseudoexon splicing.
Nucleic Acids Research
32:
1783–1791.
|
|
|
Sperling J,
Azubel M and
Sperling R
(2008)
Structure and function of the pre-mRNA splicing machine.
Structure
16:
1605–1615.
|
|
|
Sun H and
Chasin LA
(2000)
Multiple splicing defects in an intronic false exon.
Molecular and Cellular Biology
20:
6414–6425.
|
|
|
Wang Z and
Burge CB
(2008)
Splicing regulation: from a parts list of regulatory elements to an integrated splicing code.
RNA
14:
802–813.
|
|
|
Witten JT and
Ule J
(2011)
Understanding splicing regulation through RNA splicing maps.
Trends in Genetics
27:
89–97.
|
|
|
Yamaguchi H,
Fujimoto T,
Nakamura S et al.
(2010)
Aberrant splicing of the milk fat globule-EGF factor 8 (MFG-E8) gene in human systemic lupus erythematosus.
European Journal of Immunology
40:
1778–1785.
|
|
|
Zhang MQ
(1998)
Statistical features of human exons and their flanking regions.
Human Molecular Genetics
7:
919–932.
|
|
|
Zhang XH and
Chasin LA
(2004)
Computational definition of sequence motifs governing constitutive exon splicing.
Genes & Development
18:
1241–1250.
|
|
|
Zhang XH,
Leslie CS and
Chasin LA
(2005)
Dichotomous splicing signals in exon flanks.
Genome Research
15:
768–779.
|
| Further Reading |
|
|
Buratti E,
Baralle M and
Baralle FE
(2006)
Defective splicing, disease and therapy: searching for master checkpoints in exon definition.
Nucleic Acids Research
34:
3494–3510.
|
|
|
Stamm S,
Ben-Ari S,
Rafalska I et al.
(2005)
Function of alternative splicing.
Gene
344:
1–20.
|
|
|
book
Stamm S,
Smith CW and
Lurhmann R (eds)
(2011)
Alternative pre-mRNA Splicing: Theory and Protocols.
Weinheim: Wiley-VCH.
|
